Financial releases

Crossject obtains a financing up to €12 million, in two tranches

Crossject provides strategic update on priorities for 2024

Crossject to host a business briefing on commercial strategy on February 6 at 17:30 CET

Crossject to present at Biotech Showcase on January 9 at 16:30 PT

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE®

Crossject signs ZEPIZURE® commercialization agreement for northern Europe

Crossject announces initiation of coverage by ODDO BHF

Crossject reports financial results and business highlights for first half of 2023

Crossject announces significant improvement in Gaïa ESG rating

Crossject reports successful completion of European and U.S. audits for manufacturing of ZENEO® Midazolam for epileptic seizures